Technical breakthroughs in the wearable artificial kidney (WAK).

BACKGROUND The wearable artificial kidney (WAK) has been a holy grail in kidney failure for decades. Described herein are the breakthroughs that made possible the creation of the WAK V1.0 and its advanced versions V 1.1 and 1.2. DESIGN The battery-powered WAK pump has a double channel pulsatile counter phase flow. This study clarifies the role of pulsatile blood and dialysate flow, a high-flux membrane with a larger surface area, and the optimization of the dialysate pH. Flows and clearances from the WAK pump were compared with conventional pumps and with gravity steady flow. RESULTS Raising dialysate pH to 7.4 increased adsorption of ammonia. Clearances were higher with pulsatile flow as compared with steady flow. The light WAK pump, geometrically suitable for wearability, delivered the same clearances as larger and heavier pumps that cannot be battery operated. Beta(2) microglobulin (beta(2)M) was removed from human blood in vitro. Activated charcoal adsorbed most beta(2)M in the dialysate. The WAK V1.0 delivered an effective creatinine clearance of 18.5 +/- 3.2 ml/min and the WAK V1.1 27.0 +/- 4.0 ml/min in uremic pigs. CONCLUSIONS Half-cycle differences between blood and dialysate, alternating transmembrane pressures (TMP), higher amplitude pulsations, and a push-pull flow increased convective transport. This creates a yet undescribed type of hemodiafiltration. Further improvements were achieved with a larger surface area high-flux dialyzer and a higher dialysate pH. The data suggest that the WAK might be an efficient way of providing daily dialysis and optimizing end stage renal disease (ESRD) treatment.

[1]  Andrew Davenport,et al.  A wearable haemodialysis device for patients with end-stage renal failure: a pilot study , 2007, The Lancet.

[2]  K. Maeda,et al.  Push/pull hemodiafiltration: technical aspects and clinical effectiveness. , 1999, Nephron.

[3]  P. Mohr,et al.  The case for dialy dialysis: Its impact on costs and quality of life , 2001 .

[4]  M. Jaffrin,et al.  Simultaneous convective and diffusive mass transfers in a hemodialyser. , 1990, Journal of biomechanical engineering.

[5]  C. Ronco,et al.  Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. , 1996, Kidney international.

[6]  V. Wizemann,et al.  On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  S. E. Ottmers,et al.  Hemodialysis: Evidence of Enhanced Molecular Clearance and Ultrafiltration Volume by Using Pulsatile Flow , 1993, The International journal of artificial organs.

[8]  P. Kimmel,et al.  Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  H. Polaschegg,et al.  The acu-men: a new device for continuous renal replacement therapy in acute renal failure. , 1998, Kidney international.

[10]  Hans-Dietrich Polaschegg,et al.  Continuous Renal Replacement Therapy for End-Stage Renal Disease , 2005 .

[11]  E. Friedman,et al.  Will nephrologists use a wearable artificial kidney? , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[12]  Donald A Redelmeier,et al.  The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. , 2003, Kidney international.

[13]  M. Jaffrin,et al.  Rationale of filtration enhancement in membrane plasmapheresis by pulsatile blood flow. , 1987, Life support systems : the journal of the European Society for Artificial Organs.

[14]  C. Ronco,et al.  Hemodiafiltration history, technology, and clinical results. , 2007, Advances in chronic kidney disease.

[15]  B. Manns,et al.  Dialysis Adequacy and Health Related Quality of Life in Hemodialysis Patients , 2002, ASAIO journal.

[16]  S. Fukuhara,et al.  Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Kidney international.

[17]  S. Ash APPROACHES TO QUOTIDIAN DIALYSIS: The Allient Dialysis System , 2004, Seminars in dialysis.

[18]  R. Lockridge,et al.  Is HCFA’s Reimbursement Policy Controlling Quality of Care for End-Stage Renal Disease Patients? , 2001, ASAIO journal.

[19]  W Kolff,et al.  Portable/wearable artificial kidney (WAK) - initial evaluation. , 1976, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[20]  R. Lockridge DAILY HEMODIALYSIS—SELECTED TOPICS: The Direction of End‐Stage Renal Disease Reimbursement in the United States , 2004, Seminars in dialysis.

[21]  A. Davenport,et al.  Beta2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  E. Rambod,et al.  Continuous Renal Replacement Therapy for Congestive Heart Failure: The Wearable Continuous Ultrafiltration System , 2006, ASAIO journal.

[23]  J. Reynier,et al.  Continuous Arterio‐venous Hemofiltration in a Wearable Device to Treat End‐stage Renal Disease , 1986, ASAIO transactions.

[24]  C Ronco,et al.  A wearable hemofilter for continuous ambulatory ultrafiltration. , 2008, Kidney international.

[25]  Gualtiero Guadagni,et al.  A New Semiempirical Mathematical Model for Prediction of Internal Filtration in Hollow Fiber Hemodialyzers , 2006, Blood Purification.